Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of ABT-126 in Subjects with Schizophrenia (Extension of M10-855)
2012-005661-13Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nelonicline in schizophrenia, cognitive disorder (CD), sponsored by AbbVie Inc.. Started Mar 2013; status: terminated.
02
Drugs
nelonicline
03
Conditions
schizophreniacognitive disorder (CD)
Beyond the preview
Go deeper on 2012-005661-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005661-13.